Otsuji E, Yamaguchi T, Yamaguchi N, Koyama K, Imanishi J, Yamaoka N, Takahashi T
First Department of Surgery, Kyoto Prefectural University of Medicine, Japan.
Surg Today. 1992;22(4):351-6. doi: 10.1007/BF00308745.
In a previous study, we used a murine monoclonal antibody, A7, against human colon carcinoma as a drug-carrier to treat colorectal cancer. In the present study, we found that MAb A7 also reacted immunohistochemically with 73% of human pancreatic carcinoma cell lines, with the A7 antigen mainly being detected on the cell surface. However, the A7 antigen was found in only 9% of the spent media of these human pancreatic carcinoma cell lines by ELISA. On the other hand, the positive incidence of CA19-9, POA, ferritin, CEA, DU-PAN-2 and SLX in those spent media was 100%, 64%, 64%, 55%, 55% and 36%, respectively. These results suggest that the A7 antigen may only rarely be shed into the sera of pancreatic cancer patients, in which case MAb A7 could be a suitable drug-carrier in targeting chemotherapy for pancreatic cancer patients.
在先前的一项研究中，我们使用一种抗人结肠癌的鼠单克隆抗体A7作为药物载体来治疗结直肠癌。在本研究中，我们发现单克隆抗体A7在免疫组织化学上也与73%的人胰腺癌细胞系发生反应，A7抗原主要在细胞表面被检测到。然而，通过酶联免疫吸附测定法在这些人胰腺癌细胞系的用过的培养基中仅9%发现了A7抗原。另一方面，那些用过的培养基中CA19-9、POA、铁蛋白、癌胚抗原、DU-PAN-2和SLX的阳性发生率分别为100%、64%、64%、55%、55%和36%。这些结果表明，A7抗原可能很少脱落到胰腺癌患者的血清中，在这种情况下，单克隆抗体A7可能是胰腺癌患者靶向化疗的合适药物载体。
